Science Pool

The Seahorse extracellular flux analyzer uses the mitochondrial stress test to determine cellular metabolism and mitochondrial function. It detects, in real time, the effects of a compound on the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of the cell and determines potential mitochondrial toxicity. 

Read our fact sheet to learn more about our mitochondrial toxicity service using the Seahorse extracellular flux analyzer.

DOWNLOAD

Diverse modalities are typically defined as those molecules which sit outside the rule of five characteristics for small molecules. These diverse modalities are often termed beyond the rule of five molecules, and include peptides, targeted protein degraders, oligonucleotides including ASOs, siRNAs and oligoconjugates, and proteins and monoclonal antibodies. Due to their characteristics, diverse modalities may require specialist assay design or analytical methods. 

Cyprotex has expertise in assessing the ADME-Tox for various different types of diverse modalities to ensure robust data are generated. 

Read our fact sheet to learn more about our services for assessing diverse modalities.

DOWNLOAD

Pharmacological activity is often driven by free (unbound) concentration. Blood and plasma protein binding is important for understanding the pharmacokinetics of a molecule. These measurements along with others such as tissue binding, hepatocyte binding and microsomal binding can provide an insight into distribution and elimination from the body.

Read our fact sheet to learn more about our matrix binding services.

DOWNLOAD

Physicochemical properties provide an insight into the structure of a molecule and its physical behavior within a system, and they can influence its dissolution, absorption, distribution, metabolism, elimination, protein affinity and toxicity. Early assessment of a molecule's physicochemical properties supports rational compound design within drug discovery.

Read our fact sheet to learn more about our physicochemical profiling services.

DOWNLOAD

Cardiotoxicity is defined as toxicity that affects the heart. Drug-induced cardiotoxicity remains an important cause of pre-clinical and clinical drug failure. At Cyprotex, we are developing cutting-edge strategies to effectively predict toxicities at an early stage in the drug development process to guarantee the progression of safe novel pharmaceuticals and reduce later-stage attrition.

The mechanisms by which drugs can induce cardiotoxicity are diverse, ranging from functional (acute alteration of the mechanical function of the myocardium) to structural impairment (morphological damage to cardiomyocytes), and the clinical manifestations are wide-ranging, spanning from arrhythmia to myocardial dysfunction, to terminal heart failure. Cardiotoxicity generally results from the disruption of key cardiomyocyte processes affecting contractility, electrophysiology (ion channel trafficking), mitochondrial function, growth factors and cytokine regulation. Consequently, our assays have been developed to cover various readouts by combining multiple approaches to obtain a complete understanding of toxic effects.

At the 58^th Congress of the European Societies of Toxicology (Copenhagen, Eurotox 2024), we presented our latest work in cardiotoxicity prediction in the form of a poster, titled: “High-throughput transcriptomics combined with in vitro assays for cardiotoxicity risk assessment and mechanistic understanding”. Here, we investigated the effects of 148 reference compounds, (including structural and/or functional cardiotoxicants as well as non-cardiotoxicants) on human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) using high-throughput transcriptomics assessing the entire transcriptome (HT-transcriptomics), high-content imaging (HCI) and kinetic monitoring of calcium transients (CaT). Our compound set covered a broad range of mechanisms of action including ion channel inhibitors (Na⁺, K⁺, Ca²⁺), receptor modulators (adrenergic, dopamine, serotonin, histamine, acetylcholine, glucocorticoid, sulfonylurea), enzyme activities (COX, phosphodiesterase) and DNA metabolism.

Calcium transients, assessed by fast kinetic fluorescent readings, allowed a series of Ca²⁺ peak parameters to be studied including amplitude, frequency, full rise and decay time and peak width, which taken together revealed the effects of compounds on cardiomyocyte contraction. Since the calcium transients are closely associated with muscle contraction and ventricular action potentials, they can help us understand the in vivo cardiotoxicity effects of some compounds including electrocardiogram alterations such as QT interval prolongation. Additionally, HCI was used to assess any structural damage to the cardiomyocytes upon analysis of nuclei impairment, calcium homeostasis and mitochondrial function. Finally, HT-transcriptomics shed light on the transcriptional responses triggered upon compound treatment, which were further analysed for pathway enrichment and differential gene expression.

This multi-parametric approach allowed the identification of the readout showing the lowest minimum effective concentration (MEC). Compounds were then classified as cardiotoxic if the MEC value was below a specific maximum plasma concentration (C_max) threshold calculated using in vivo literature cardiotox classifications. Additionally, AI/Machine Learning (ML) models were developed to predict cardiotoxicity using a 20x C_max threshold and a tox score threshold. This allowed the classification of compounds as cardiotoxic if the true C_max (historical in vivo response) was above the predicted safe C_max, giving excellent prediction metrics with 78.7% sensitivity, 86.7% specificity and 81.4% accuracy.

Finally, testing dynamic C_max thresholds and different assay combinations proved useful to effectively predicting cardiotoxicity risk with excellent accuracy, whilst assigning more weight to specificity over sensitivity to avoid losing valuable drug candidates due to false-positive risks. The best predictions were achieved by combining HT-transcriptomics AI/ML modelling (20x C_max), HCI (1x C_max) and CaT (2x C_max) endpoints, with 85.9% sensitivity, 84.1% specificity and 85.3% accuracy.

Future work will involve further expansion of our reference compound list to cover an even larger range of mechanisms and chemical space, and to explore the transcriptomics pathway endpoints by performing a Point of Departure (PoD) using Benchmark Dose (BMD) analysis approach, for both hiPSC-CMs and organotypic 3D models which are likely to be more representative of the in vivo tissue structurally and functionally.

Interested in learning more?

Contact us to discuss your project.

Request the poster

Membrane permeability plays an important role in oral absorption. Cyprotex offers a range of in vitro permeability assays to understand passive permeability or transporter-mediated effects. 

Read our fact sheet to learn more about our in vitro permeability services.

DOWNLOAD

Understand if your investigational drug has the potential to be a perpetrator (precipitant) of transporter-mediated drug-drug interactions by evaluating if it is an inhibitor of drug transporters.

Read our fact sheet to learn more about our transporter inhibition service.

DOWNLOAD

Understand if your investigational drug is a potential victim (object) of transporter-mediated drug-drug interactions by evaluating if it is a substrate of drug transporters.

Read our fact sheet to learn more about our transporter substrate identification service.

DOWNLOAD

Learn more about how Cyprotex can support you in discovery bioanalysis for small molecules and biotherapeutics (including peptides, oligonucleotides and protein degraders).

Read our fact sheet to find out more about our non-regulatory bioanalysis service.

DOWNLOAD

Learn more about how Cyprotex can support you in understanding the metabolism of your compounds by identifying which metabolites are formed during in vitro and in vivo studies.

Read our fact sheet to learn more about our metabolite profiling and identification service.

DOWNLOAD